Avis et décisions de la HAS
La fiche de bon usage du médicament intitulée « Fasenra (benralizumab) et Nucala (mépolizumab) dans le traitement de l’asthme sévère», ci-jointe, est adoptée.
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
s8y3y5sZg7jTUDLW
